Researchers are putting immune cells on a diet


Lycera is evaluating an improved version of that molecule in people with psoriasis or ulcerative colitis in part because it’s easier to test drugs on those diseases than on lupus, whose symptoms affect more organs and are harder to track. Unlike the adalimumab that Jeremy Glick injects, this drug can be taken in pill form. Lycera plans to announce the results of its two trials later this year.